Aclarion, Inc.
Aclarion, Inc. is a U.S.-based medical technology and services company whose core offering is Nociscan, a report delivered to medical professionals to help evaluate spinal pain. The company monetizes its service by generating and delivering these reports, rather than by selling a traditional physical product. Its recent filings indicate that substantially all revenue comes from the United States and the United Kingdom, with UK growth improving after local coverage decisions. Aclarion is still in an early commercialization and funding phase, relying on equity and debt financings to support operations while it expands payer coverage and scan volumes.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDiagnostic reports delivered to medical professionals for spinal pain assessment and related clinical decision support.
Field support, partner coordination, and commercialization activities that help drive report adoption and utilization.
Customers
Aclarion sells primarily to medical professionals and healthcare providers that order or use Nociscan reports in the evaluation of spinal pain. The company’s filings indicate that revenue is generated from contracts with customers in the United States and the United Kingdom, so payer coverage and local reimbursement decisions are important to demand. Growth in the UK has been tied to recent local coverage decisions, showing that adoption depends on insurance access as much as clinical interest. The customer base is therefore a mix of clinicians, healthcare delivery organizations, and the reimbursement ecosystem that enables those reports to be used at scale.
Physicians and other clinicians who order Nociscan reports to support diagnosis and treatment decisions for spinal pain.
Hospitals, clinics, and care networks that use the service in patient workflows and need reimbursement-supported adoption.
Customers in the United Kingdom whose utilization has increased following local coverage decisions and broader payer access.
U.S. customers that buy the service where contract terms and reimbursement support the use of Nociscan reports.
Strategy
Aclarion’s near-term strategy is to expand scan volumes and increase the number of insurance payors that cover or support Nociscan usage, especially in the UK where recent coverage decisions have already improved revenue. The company is also focused on maintaining commercialization momentum while managing a capital structure that has depended on repeated equity and debt financings. Because revenue is concentrated in a single service line, scaling adoption of Nociscan is central to improving operating leverage and reducing dependence on external funding. The strategy therefore combines payer access, market expansion, and cash preservation.
Coverage decisions directly affect whether clinicians can order Nociscan reports at scale.
Higher utilization is the main driver of revenue growth in a single-service model.
The company has ongoing operating losses and depends on external capital to fund commercialization.
Geography
Aclarion states that substantially all of its revenue is generated from contracts with customers in the United States and the United Kingdom. The company specifically highlighted stronger UK revenue growth in recent quarters after local coverage decisions, making the UK an important growth market rather than just a small export channel. The U.S. remains the company’s home market and likely the base for operations, commercialization, and investor funding. Geography matters because reimbursement, payer coverage, and healthcare adoption differ by market, so revenue growth depends on local access conditions rather than a uniform global rollout.
Risks
Aclarion faces execution risk because its business depends on a single revenue source, Nociscan report delivery, so any slowdown in adoption would quickly affect growth. Reimbursement and payer coverage are critical because the company’s recent revenue improvement was tied to UK local coverage decisions, making market access a key dependency. As a small reporting company with limited operating scale, it also faces financing risk and may need to continue raising capital to support commercialization and working capital. More broadly, medical diagnostics and healthcare services businesses face regulatory, reimbursement, and clinical adoption risk, and cross-border revenue concentration in the U.S. and UK creates exposure to changes in local healthcare policy and payor behavior.
Revenue comes from one source, so the company lacks diversification if adoption slows or a competing approach gains traction.
Exposure: Nociscan report delivery
Revenue growth in the UK was driven by local coverage decisions, showing that payer access is a primary demand driver.
Exposure: United Kingdom and United States healthcare payors
The company has funded operations through equity and debt offerings and expects to need capital to continue commercialization.
Exposure: Operating cash burn and capital markets access
The business depends on clinicians ordering reports at increasing volumes, which can be slow in healthcare workflows.
Exposure: Physician and provider adoption
Accounting
Judgemental itemsRevenue is tied to service delivery and contract existence, so timing of report completion and customer acceptance affects reported sales.
Impact: Can shift revenue between quarters depending on volume and contract timing
Stock options and RSUs create non-cash compensation expense, and valuation changed after the IPO from private estimates to market prices.
Impact: Affects operating expenses and dilution
Management relies on estimates for assets, liabilities, and contingent items, which can change reported results if assumptions shift.
Impact: Can affect accruals, expenses, and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Allurion Technologies, Inc.
ALURW · Surgical & Medical Instruments & Apparatus
Acrivon Therapeutics, Inc.
ACRV · Pharmaceutical Preparations
Nexalin Technology, Inc.
NXL · Electromedical & Electrotherapeutic Apparatus
Axogen, Inc.
AXGN · Electromedical & Electrotherapeutic Apparatus
agilon health, inc.
AGL · Services-Misc Health & Allied Services, NEC
Last updated: 24/09/2026